VERTEX PHARMACEUTICALSInsider Trading & SEC Form 4 Analysis
Institutional analysis of internal capital flows based on SEC Form 4 filings.
Automated_Intelligence_Report :: VRTX
Algorithmic analysis of recent insider trading activity for VRTX reveals a bearish posture among the C-suite and board members. Based on the latest SEC Form 4 filings, we have tracked capital events executed by 17 distinct corporate insiders. The aggregate nominal exposure during this reporting cycle reached $116.01M.
Market dynamics show a negative net capital flow of $70.25M when isolating open-market purchases versus open-market sales. The trading volume is heavily weighted towards open-market executions, providing a clearer signal of insider conviction regarding current valuation levels compared to option-based equity grants.
From a microstructural perspective, the most significant liquidity event was a divestment by Sachdev Amit (Officer/Other), which accounts for a major share of the recent outflow. Continuous monitoring of these Tier-1 actors is essential, as their liquidity decisions often precede material corporate events or reflect an informed, asymmetric perspective on the future performance of VRTX.
$116.01M
USD NOMINAL VALUE17
UNIQUE C-SUITE ENTITIES2026.05.15
ISO_8601 FORMATAutomated_Queries :: Frequently Asked Questions
>Who is currently buying VRTX stock?
Our algorithmic tracking of SEC Form 4 filings indicates no significant open-market buying activity by major executives for VRTX in the recent reporting period.
>Are VRTX insiders selling their shares?
Yes, we have tracked $70.25M in recent insider liquidations. The most notable recent seller is Sachdev Amit, who executed the largest single offload.
>What is the overall insider sentiment for VRTX?
The short-term structural capital flow indicates a BEARISH sentiment, with a net flow of $70.25M generated by 17 active C-Suite entities.